ERBB2 and adenocarcinoma: HER2-mutant lung cancer patients had a median age of 58 (range 44–77 years) and mutations were more common in females (p<0.001),non-smokers (p = 0.034) and adenocarcinomas (p = 0.002)(Table 1).